Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.

Wolfgang Kruis,Britta Siegmund, Konrad Lesniakowski,Vladimir Simanenkov, Ludmila Khimion, Marcin Sobon,Glebs Delmans,Svetlana V Maksyashina, Oleg A Sablin,Juris Pokrotnieks,Yuriy Mostovoy, Olena Datsenko,Sayar Abdulkhakov, Andriy Dorofeyev,Olena Levchenko,Olga Alexeeva,Pavel Andreev, Ivan P Kolesnik,Emese Mihaly,Orest Abrahamovych, Malgorzata Baluta,Nataliia Kharchenko,Neshta Viacheslav,Yury Uspenskiy,Michael Vieth,Ralf Mohrbacher,Ralph Mueller,Roland Greinwald

Journal of Crohn's & colitis（2022）

引用 4|浏览11

暂无评分

摘要

In patients with ulcerative proctitis, budesonide 4 mg suppository was non-inferior to budesonide 2 mg foam in efficacy, and both were safe and well tolerated.

查看译文

关键词

Clinical trials,budesonide,rectal foam,rectal suppository,ulcerative proctitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要